WYETH-AYERST COMMITS TO CHARACTERIZATION OF PREMARIN, FDA SAYS; GENERIC CONJUGATED ESTROGENS MAY NOT BE APPROVED UNTIL PREMARIN IS CHARACTERIZED

Wyeth-Ayerst has committed to characterizing the composition of Premarin, FDA said in a May 5 memorandum explaining its current decision not to approve generic versions of the conjugated estrogens product.